Serummonitorering af olanzapin under antipsykotisk behandling

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Serummonitorering af olanzapin under antipsykotisk behandling. / Linnet, Kristian; Olesen, Ole Vendelin.

I: Ugeskrift for Laeger, Bind 162, Nr. 36, 04.09.2000, s. 4802-4805.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Linnet, K & Olesen, OV 2000, 'Serummonitorering af olanzapin under antipsykotisk behandling', Ugeskrift for Laeger, bind 162, nr. 36, s. 4802-4805.

APA

Linnet, K., & Olesen, O. V. (2000). Serummonitorering af olanzapin under antipsykotisk behandling. Ugeskrift for Laeger, 162(36), 4802-4805.

Vancouver

Linnet K, Olesen OV. Serummonitorering af olanzapin under antipsykotisk behandling. Ugeskrift for Laeger. 2000 sep. 4;162(36):4802-4805.

Author

Linnet, Kristian ; Olesen, Ole Vendelin. / Serummonitorering af olanzapin under antipsykotisk behandling. I: Ugeskrift for Laeger. 2000 ; Bind 162, Nr. 36. s. 4802-4805.

Bibtex

@article{bfa2de097d544f52a5160b60b1e31504,
title = "Serummonitorering af olanzapin under antipsykotisk behandling",
abstract = "Olanzapine steady-state serum concentrations of 334 patients were measured by high pressure liquid chromatography. The patients were subjected to routine therapeutic drug monitoring of antipsychotic treatment. In cases with more than one serum determination per patient, only the first measurement was included. Eighty-four percent of the patients received daily doses in the recommended range from 5 to 20 mg. The interval 25-140 nmol/1 covered about 80% of the concentrations observed for the daily dose range 5-20 mg. This interval may be used as a reference for therapeutic drug monitoring of olanzapine, indicating whether a patient has a typical or an atypical concentration level at a given dose. Such a judgment may be helpful in situations characterized by side effects, insufficient effect, doubts about compliance or possible pharmacokinetic interactions.",
author = "Kristian Linnet and Olesen, {Ole Vendelin}",
year = "2000",
month = sep,
day = "4",
language = "Dansk",
volume = "162",
pages = "4802--4805",
journal = "Ugeskrift for Laeger",
issn = "0041-5782",
publisher = "Almindelige Danske Laegeforening",
number = "36",

}

RIS

TY - JOUR

T1 - Serummonitorering af olanzapin under antipsykotisk behandling

AU - Linnet, Kristian

AU - Olesen, Ole Vendelin

PY - 2000/9/4

Y1 - 2000/9/4

N2 - Olanzapine steady-state serum concentrations of 334 patients were measured by high pressure liquid chromatography. The patients were subjected to routine therapeutic drug monitoring of antipsychotic treatment. In cases with more than one serum determination per patient, only the first measurement was included. Eighty-four percent of the patients received daily doses in the recommended range from 5 to 20 mg. The interval 25-140 nmol/1 covered about 80% of the concentrations observed for the daily dose range 5-20 mg. This interval may be used as a reference for therapeutic drug monitoring of olanzapine, indicating whether a patient has a typical or an atypical concentration level at a given dose. Such a judgment may be helpful in situations characterized by side effects, insufficient effect, doubts about compliance or possible pharmacokinetic interactions.

AB - Olanzapine steady-state serum concentrations of 334 patients were measured by high pressure liquid chromatography. The patients were subjected to routine therapeutic drug monitoring of antipsychotic treatment. In cases with more than one serum determination per patient, only the first measurement was included. Eighty-four percent of the patients received daily doses in the recommended range from 5 to 20 mg. The interval 25-140 nmol/1 covered about 80% of the concentrations observed for the daily dose range 5-20 mg. This interval may be used as a reference for therapeutic drug monitoring of olanzapine, indicating whether a patient has a typical or an atypical concentration level at a given dose. Such a judgment may be helpful in situations characterized by side effects, insufficient effect, doubts about compliance or possible pharmacokinetic interactions.

UR - http://www.scopus.com/inward/record.url?scp=0034605092&partnerID=8YFLogxK

M3 - Tidsskriftartikel

C2 - 10994377

AN - SCOPUS:0034605092

VL - 162

SP - 4802

EP - 4805

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

SN - 0041-5782

IS - 36

ER -

ID: 230032950